Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
37
CATX Quote, Financials, Valuation and Earnings
Last price:
$2.2200
Seasonality move
:
1.77%
Day range:
$2.4000 - $2.6000
52-week range:
$1.6000 - $19.0500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.73x
P/B ratio:
0.62x
Volume:
504.6K
Avg. volume:
832.7K
1-year change:
-86.57%
Market cap:
$179.9M
Revenue:
--
EPS (TTM):
-$1.20
Analysts' Opinion
-
Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.3929, Perspective Therapeutics has an estimated upside of 492.3% from its current price of $2.4300.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.0000 representing 100% downside risk from its current price of $2.4300.
Fair Value
-
According to the consensus of 11 analysts, Perspective Therapeutics has 492.3% upside to fair value with a price target of $14.3929 per share.
CATX vs. S&P 500
-
Over the past 5 trading days, Perspective Therapeutics has underperformed the S&P 500 by -2.24% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Perspective Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Perspective Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Perspective Therapeutics reported revenues of --.
Earnings Growth
-
Perspective Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Perspective Therapeutics reported earnings per share of -$0.61.
Enterprise value:
-45.3M
EV / Invested capital:
--
Price / LTM sales:
15.73x
EV / EBIT:
--
EV / Revenue:
-4.55x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
0.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $9M | -- | -- | -$5.2M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$40.9M | -$66.8M | -$11.7M | -$20.9M | |
| EBITDA | -- | -$39M | -$78.1M | -$11.3M | -$41.6M | |
| Diluted EPS | -- | -$4.98 | -$1.20 | -$0.88 | -$0.61 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.3M | $63.6M | -- | $16.8M | $231.2M | |
| Total Assets | $15.5M | $67.3M | -- | $97.9M | $341.1M | |
| Current Liabilities | $1.3M | $1.8M | -- | $15.7M | $18.2M | |
| Total Liabilities | $2.7M | $2.9M | -- | $22.7M | $50.4M | |
| Total Equity | $12.8M | $64.4M | -- | $75.2M | $290.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$36.9M | -$18.3M | -$9M | -$26.6M | |
| Cash From Investing | -- | $24.4M | -$218.9M | -$89K | -$138.6M | |
| Cash From Financing | -- | $785K | $289.4M | $352K | $345K | |
| Free Cash Flow | -- | -$38M | -$72.7M | -$9.1M | -$41.2M | |
CATX
Sector
Market Cap
$179.9M
$35.1M
Price % of 52-Week High
12.76%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-86.58%
-40.62%
Beta (5-Year)
1.112
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.4488
200-day SMA
Sell
Level
$7.3321
Bollinger Bands (100)
Sell
Level
2.2512 - 3.4112
Chaikin Money Flow
Sell
Level
-44.3M
20-day SMA
Buy
Level
$2.1565
Relative Strength Index (RSI14)
Buy
Level
55.7733
ADX Line
Buy
Level
21.9561
Williams %R
Neutral
Level
-24.3604
50-day SMA
Buy
Level
$2.3252
MACD (12, 26)
Buy
Level
0.0598
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
52.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Stock Forecast FAQ
In the current month, CATX has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $14.3929.
-
Where Will Perspective Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Perspective Therapeutics share price will rise to $14.3929 per share over the next 12 months.
-
What Do Analysts Say About Perspective Therapeutics?
Analysts are divided on their view about Perspective Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics is a Sell and believe this share price will drop from its current level to $6.0000.
-
What Is Perspective Therapeutics's Price Target?
The price target for Perspective Therapeutics over the next 1-year time period is forecast to be $14.3929 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CATX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Perspective Therapeutics is a Buy. 10 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CATX?
You can purchase shares of Perspective Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics shares.
-
What Is The Perspective Therapeutics Share Price Today?
Perspective Therapeutics was last trading at $2.2200 per share. This represents the most recent stock quote for Perspective Therapeutics. Yesterday, Perspective Therapeutics closed at $2.4300 per share.
-
How To Buy Perspective Therapeutics Stock Online?
In order to purchase Perspective Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
